Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

Polypeptides

Goserelin Acetate 145781-92-6

Goserelin Acetate 145781-92-6

98% up by HPLC, EP
  • Product Details

Product Information


Product name

Goserelin Acetate

CAS No.

145781-92-6

Molecular Formula

C59H84N18O14.C2H4O2

Molecular Weight

1269.41

Molecule Structure

Quality Standard

98% up by HPLC, EP

Appearance

White slightly yellowish powder


COA of Goserelin Acetate


Items

Specification

Results

Appearance

White slightly yellowish powder

Conforms

Appearance of solution

Clear, colorless to slightly colored solution in water(10mg/ml)

Conforms

Purity(HPLC)

> 98%

99.3%

Peptide

80%


Amino acids

Arg:0.9-1.1

Leu: 0.9-1.1

Tyr: 0.9-1.1

Glu: 0.9-1.1

Pro: 0.9-1.1

His: 0.9-1.1

Ser: 0.9-1.1

Trp:Detected

1.08

1.00

0.98

1,06

1.07

1.06

0.97

Detected

Specific optical rotation

-52- -56°([a]20D(c=0.2 water))

-54.6°

Related substances (HPLC)

Total impurities: 2.5%
Any impurity:
1.5%

0.9%

0.3%

Water (Karl Fischer)

10.0 %

3.8%

Acetate content (HPLC)

4.5%-15.7%

10.3%

Conclusion

Complies with the standard.


Usage


Function of Goserelin Acetate


Goserelin acetate is an analog of gonadotropin releasing hormone. It can inhibit ovarian function to make premenopausal women reach the level of postmenopausal hormones. At the same time, it can also protect the ovaries and follicles during chemotherapy. It protects the patient's ovaries from chemotherapy damage, restores ovarian function after stopping chemotherapy, and protects fertility. For premenopausal patients, after stopping goserelin acetate sustained-release implants, menstrual and ovarian function can be restored. At the same time, goserelin acetate is also used in prostate cancer to play a role in drug castration.


Application of Goserelin Acetate


1. Prostate cancer: This product is suitable for prostate cancer that can be treated with hormones.

2. Breast cancer: suitable for breast cancer in premenopausal and perimenopausal women who can be treated with hormones.

3. Endometriosis: Relieving symptoms includes reducing pain and reducing the size and number of endometrial damage.

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

LIRAGLUTIDE
Liraglutide 204656-20-2
Product Information Product name Liraglutide Sequence H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu- Glu-Gly-Gln-Ala-Ala-Lys[N6-[N-(1-oxohexadecyl)-L-γ-glutamyl]- -Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH CAS No. 204656-20-2 Molecular Formula C172H265N43O51 Molecular Weight 3751.20 Storage  2~8℃ Appearance White to off-white crystalline powder COA of Liraglutide Test Specification Results Appearance: White to off-white crystalline powder or lumps White powder Identity: 3751.2±1.0 3751.1 Purity (By HPLC) : Not Less than 98.0%; 99.51% Residual solvents: ≤0.25%total; ≤0.1%individual; ≤0.01%CH2CN Complies Related Peptide Total Impurity ≤ 2.0% Largest Single Impurity ≤ 1.0% TI =0.41% LSI =0.25% Peptide Content: Not Less than 85.0% 87.7% Water (K.F.): Not more than 5% 4.2% Acetate acid: Not more than 10% 8.1% Bacterial Endotoxins Not more than 50IU/mg Complies Usage Function and Usage of Liraglutide 204656-20-2 1、 Type 2 diabetes Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion. In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes: ·         Liraglutide acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia. ·         Liraglutide has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies). ·         Liraglutide decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride. ·         Liraglutide lowers blood triglyceride levels. 2、Obesity Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
nonapeptide-1
Nonapeptide-1 158563-45-2
99% up by HPLC
Linaclotide
Linaclotide 851199-59-2
98% up, Medical Grade
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact